医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Spain VHIR Selects Macrogen as the Genomics Service Partner

2014年10月13日 PM10:00
このエントリーをはてなブックマークに追加


 

BARCELONA, Spain & SEOUL, South Korea

The Vall d’Hebron Research Institute (VHIR, www.vhir.org) in Barcelona, Spain, and the world-leading Genomics services company Macrogen (www.macrogen.com) (KRX 038290) in Seoul, South Korea, announced that they had signed a comprehensive Genomics service partnership agreement including Macrogen X-Genome (the Xpressway to Genome) services.

According to this agreement, Macrogen will provide various Genomics services including both the capillary sequencing service and the state-of-art next-generation sequencing (NGS) service to VHIR researchers. This agreement reinforces VHIR’ scientific and technical support services in an effort to strengthen its researcher’s capacity to discover and implement novel diagnosis and treatment measures. In this sense, VHIR’s researchers will benefit from the Macrogen-VHIR special program based on Macrogen’s comprehensive Genomics service portfolio. VHIR’s staff, composed of 1,200 researchers (mostly clinicians), is aimed to achieve a direct translation from research to applications, with the final goal of offering Vall d’Hebron Hospital patients the benefit of the most advanced knowledge. By means of this agreement, Macrogen will partner with VHIR to achieve its objective.

In fact, Macrogen is the only European provider of the Illumina HiSeq X Ten sequencing system based large-scale Human whole-genome sequencing service, also known as Macrogen’s ‘X-genome (the Xpressway to Genome)’ service. Optimized for large-scale human genome analysis projects, the HiSeq X Ten sequencing system is capable of analyzing the genomes of 16 people within 3 days for a cost of less than 1,000 dollars, giving rise to expectations that it will pave the way to a new era of human genome sequencing. In January of this year, Macrogen became the first commercial service provider to sign a preferred supply agreement for the HiSeq X Ten system with Illumina.

Whole-genome sequencing using the ‘X-Genome’ service is the most comprehensive approach to cataloging an individual’s genetic constitution in a single assay. As a result, cost-effective, highly accurate human whole-genome is poised to become a mainstay in translational medicine.

Many other NGS applications as exome sequencing, metagenomics, transcriptome sequencing, and targeted sequencing of disease-associated regions, etc. are offered by Macrogen and can now be accessed in a very convenient manner through the guidance of VHIR’ specialized staff working on the technical and scientific support Units including UAT (High Technology Unit) and UEB (Statistics and Bioinformatics Unit).

“Given that VHIR’s researchers’ main efforts are dedicated to enhance citizen’s health by applying the latest and more powerful therapeutics and diagnostics tools to patients, the agreement with Macrogen, specially regarding the X-Genome, will definitely be a major advance,” said Dr. Joan Comella, VHIR’s Director.

“Through this agreement, we can provide a variety of NGS Sequencing service to VHIR. Specially, Macrogen’s X-genome service can help VHIR’s efforts to translate genomics research into an improved life quality for patients,” said Macrogen’s CEO, Dr. Hyungtae Kim.

About Vall d’Hebron Research Institute

VHIR is a public sector institution that promotes and develops innovative biomedical research at the University Hospital Vall d’Hebron, located in Barcelona, Spain. VHIR is oriented towards finding solutions to the health problems of the citizens and has the will to contribute to the scientific, educational, social and economic development within its area of competence.

Find out more at http://www.vhir.org

About Macrogen

Macrogen, Inc. (www.macrogen.com), based in Seoul, Korea, is a world leading service provider in high-quality gene analysis and has enjoyed stable and steady growth since 1997. Macrogen Inc. has been dedicated to provide a reliable and efficient service of DNA Sequencing and bioinformatics with profound knowledge and unbeatable amount experience over 17 years. The company’s diverse offerings include DNA sequencing, next generation sequencing, microarray analysis, oligonucleotide synthesis, DNA chip and genetically engineered mice services. We serve over +17,000 customers from academic research and industry in 120 countries around the globe and have subsidiary companies in USA, Japan and Europe, headquartered in South Korea.

Find out more at http://www.macrogen.com

CONTACT

Macrogen Inc.
Yonghwan Kang, +82-2-2113-7113
snatch@macrogen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表